Biomerica (NASDAQ:BMRA) Stock Passes Above 200 Day Moving Average – Time to Sell?

Shares of Biomerica, Inc. (NASDAQ:BMRA) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.44 and traded as high as $0.72. Biomerica shares last traded at $0.71, with a volume of 309,461 shares trading hands.

Biomerica Stock Up 4.8 %

The firm has a 50-day moving average of $0.65 and a two-hundred day moving average of $0.44. The stock has a market capitalization of $13.02 million, a price-to-earnings ratio of -2.09 and a beta of -1.16.

Biomerica (NASDAQ:BMRA) last issued its earnings results on Tuesday, January 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. Biomerica had a negative net margin of 100.52% and a negative return on equity of 90.19%.

Hedge Funds Weigh In On Biomerica

A hedge fund recently raised its stake in Biomerica stock. Granahan Investment Management LLC grew its stake in Biomerica, Inc. (NASDAQ:BMRA) by 24.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 658,767 shares of the company’s stock after buying an additional 131,306 shares during the period. Granahan Investment Management LLC owned approximately 3.59% of Biomerica worth $198,000 as of its most recent SEC filing. 22.28% of the stock is owned by institutional investors and hedge funds.

About Biomerica

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.